Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimotuzumab + gemcitabine + capecitabine
- Development stage
- Phase 3
- Lead developer
- Biotech Pharmaceutical Corp
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
nimotuzumab + gemcitabine + capecitabine is a combination therapy regimen being evaluated as a postoperative adjuvant treatment for resected pancreatic ductal adenocarcinoma. The regimen consists of nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), combined with the chemotherapy doublet GX, which comprises gemcitabine and capecitabine. Nimotuzumab works by binding to EGFR, thereby inhibiting tumor cell proliferation, inducing apoptosis, and reducing angiogenesis. Gemcitabine is a nucleoside analog that interferes with DNA synthesis, while capecitabine is an oral fluoropyrimidine carbamate that is converted to 5-fluorouracil within the body, acting as an antimetabolite. This combination is primarily being developed and studied by the Tianjin Medical University Cancer Institute and Hospital to improve disease-free and overall survival in patients following surgical resection of pancreatic tumors.
- Other names
- Nimotuzumab + GXNimotuzumab + Gemcitabine + Capecitabine
02
Targets
Beyond the preview
Go deeper on nimotuzumab + gemcitabine + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimotuzumab + gemcitabine + capecitabine.